Caio Max Rocha Lima to Adenocarcinoma
This is a "connection" page, showing publications Caio Max Rocha Lima has written about Adenocarcinoma.
Connection Strength
1.682
-
Merchan JR, Ferrell A, Macintyre J, Ciombor KK, Levi J, Ribeiro A, Sleeman D, Flores A, Lopes G, Rocha-Lima CM. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Am J Clin Oncol. 2012 Oct; 35(5):446-50.
Score: 0.344
-
Bayraktar UD, Chen E, Bayraktar S, Sands LR, Marchetti F, Montero AJ, Rocha-Lima CM. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma? Cancer. 2011 Jun 01; 117(11):2364-70.
Score: 0.304
-
Shoemaker LK, Arora U, Rocha Lima CM. 5-fluorouracil-induced coronary vasospasm. Cancer Control. 2004 Jan-Feb; 11(1):46-9.
Score: 0.188
-
Bhargava P, Jani CR, Savarese DM, O'Donnell JL, Stuart KE, Rocha Lima CM. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):23-6.
Score: 0.183
-
Khushman M, Dempsey N, Maldonado JC, Loaiza-Bonilla A, Velez M, Carcas L, Dammrich D, Hurtado-Cordovi J, Parajuli R, Pollack T, Harwood AP, Macintyre J, Tzeng CW, Merchan JR, Restrepo MH, Akunyili II, Ribeiro A, Narayanan G, Portelance L, Sleeman D, Levi JU, Lima CM, Hosein PJ. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology. 2015 Nov-Dec; 15(6):667-73.
Score: 0.106
-
Wolpin BM, O'Reilly EM, Ko YJ, Blaszkowsky LS, Rarick M, Rocha-Lima CM, Ritch P, Chan E, Spratlin J, Macarulla T, McWhirter E, Pezet D, Lichinitser M, Roman L, Hartford A, Morrison K, Jackson L, Vincent M, Reyno L, Hidalgo M. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol. 2013 Jul; 24(7):1792-1801.
Score: 0.089
-
Narayanan G, Hosein PJ, Arora G, Barbery KJ, Froud T, Livingstone AS, Franceschi D, Rocha Lima CM, Yrizarry J. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol. 2012 Dec; 23(12):1613-21.
Score: 0.087
-
Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, Rocha-Lima CS, Safran H, Lenz HJ, Chiorean EG. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013 Jan; 17(1):94-100; discussion p. 100-1.
Score: 0.087
-
Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, McGreivy J, Bray SL, Hei Y, Feigal EG, Loh E, Fuchs CS. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012 Nov; 23(11):2834-2842.
Score: 0.084
-
Bayraktar UD, Bayraktar S, Hosein P, Chen E, Koniaris LG, Rocha-Lima CM, Montero AJ. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma. Med Oncol. 2012 Sep; 29(3):1707-10.
Score: 0.081
-
Burris HA, Rosen LS, Rocha-Lima CM, Marshall J, Jones S, Cohen RB, Kunkel LA, Loo D, Baughman J, Stewart SJ, Lewis N. Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma. Clin Cancer Res. 2010 Mar 01; 16(5):1673-81.
Score: 0.072
-
Marsh Rde W, Rocha Lima CM, Levy DE, Mitchell EP, Rowland KM, Benson AB. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2007 Feb; 30(1):26-31.
Score: 0.058